Inclusion-Body Myositis Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Condition: Sporadic Inclusion Body MyositisInterventions: Drug: Bimagrumab; Drug: PlaceboSponsor: Novartis PharmaceuticalsNot yet recruiting - verified October 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 9, 2015 Category: Research Source Type: clinical trials
